Tuesday, 16 April 2024


Japan's Shionogi seeks China approval for COVID-19 treatment

08 July 2022 | News

Shionogi's S-217622 is an orally administered antiviral drug for COVID-19

Image credit: shutterstock

Image credit: shutterstock

Shionogi & Co., has announced that a joint venture between Shionogi and Ping An Life Insurance Company of China, , Ping An-Shionogi Co., Ltd. has initiated the submission of preparation materials for an application for new drug approval application for S-217622, an orally administered antiviral drug for COVID-19, to the Center for Drug Evaluation, NMPA (CDE).

Prior to the formal submission of the new drug application, Ping An-Shionogi has submitted a communication meeting application to the CDE for this therapeutic drug to facilitate the new drug application process.

S-217622 is an oral antiviral agent administered once daily for 5 days that is capable of suppressing the growth of SARS-CoV-2 by selectively inhibiting the 3CL protease. So far, S-217622 has shown the ability to rapidly reduce viral load, the good tolerability, and has been suggested to improve a composite score of five “respiratory and fever-related” symptoms. It is expected to contribute to the COVID-19 treatment in China, after approval.

As the COVID-19 pandemic continues to have a significant impact on people’s lives globally, Shionogi will continue the development of COVID-19 therapeutic agents in Japan and other countries to contribute to the restoration of safety and security to society.

 

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account